Axogen Prices $208.7 Million Stock Offering to Fund BioCircuit Acquisition

Axogen has priced an underwritten public offering of 4.91 million common shares at $42.50 each, putting expected gross proceeds at about $208.7 million before underwriting discounts, commissions and other offering expenses. The peripheral nerve repair company said it intends to use substantially all of the net proceeds to fund its planned $200 million cash acquisition of BioCircuit Technologies and related fees and expenses.

All of the shares in the base offering are being sold by Axogen rather than existing shareholders. The company also granted the underwriters a 30-day option to buy as many as 736,500 additional shares at the public offering price, less underwriting discounts and commissions. Axogen expects the offering to close on September 11, subject to customary closing conditions.

The financing and acquisition are linked in purpose but not legally dependent on each other. Axogen said the stock sale is not conditioned on the BioCircuit acquisition closing. If the acquisition does not go through, the company plans to use the offering proceeds for general corporate purposes, including working capital and capital expenditures. The terms appear in Axogen’s September 10 Form 8-K.

The base offering raises less than $208.7 million after underwriting

The $208.7 million figure is the expected gross amount, not the cash Axogen will ultimately have available. Multiplying 4.91 million shares by the $42.50 public price gives $208.675 million. The same SEC filing says the underwriters will pay Axogen $39.95 per share, which implies roughly $196.2 million to the company from the base sale before other offering expenses.

That distinction matters because the announced purchase price for BioCircuit is $200 million in cash at closing, subject to customary adjustments for cash, indebtedness, expenses and net working capital. Axogen will also withhold $1 million of the estimated consideration at closing pending the final post-closing purchase-price adjustment. The company has not said that the base stock sale alone will equal every dollar needed for the acquisition and its related costs.

Axogen does have additional financing flexibility. The underwriters’ option could add up to 736,500 shares to the offering, and Axogen reported $113.4 million of cash, cash equivalents, restricted cash and investments at the end of the second quarter. Its July investor materials also said the company had no debt obligations at that point. Still, the acquisition agreement requires Axogen to obtain sufficient funding within 90 days of signing, and failure to do so would breach the agreement. The acquisition itself is not subject to a financing condition.

BofA Securities, Jefferies and Wells Fargo Securities are serving as lead book-running managers for the stock sale. Mizuho Securities USA is also a bookrunner, while Lake Street Capital Markets is acting as co-manager. The shares are being offered under Axogen’s existing shelf registration statement filed with the Securities and Exchange Commission in January.

BioCircuit adds a sutureless nerve-repair device to Axogen’s portfolio

BioCircuit is an Atlanta-based medical-device company focused on peripheral nerve repair and neuromodulation. Its core business includes NerveTape and ConformaWrap. NerveTape is designed to align, connect and protect transected peripheral nerves without relying on microsutures, which places the product directly alongside Axogen’s existing nerve-repair products and surgeon relationships.

Axogen’s investor presentation describes BioCircuit as a relatively small but rapidly growing commercial business. The company reported about $11 million of BioCircuit revenue in 2025 and an annualized run rate of roughly $24 million based on the second quarter of 2026. It also cited gross margins of about 80%, positive standalone EBITDA, more than 14,000 NerveTape implants sold and more than 400 hospital and ambulatory surgery center accounts as of June 2026. Those figures are company-provided metrics rather than independently audited forecasts of future performance.

Regulatory wording around NerveTape also deserves precision. Axogen’s acquisition announcement refers to the product in one headline description as FDA-approved, but the Food and Drug Administration’s 510(k) record for NerveTape shows a February 12, 2024 substantial-equivalence decision for a Class II nerve cuff. MarketReview therefore describes NerveTape as FDA-cleared. The FDA record lists the device for repair of peripheral nerve discontinuities where gap closure can be achieved by flexion of the extremity.

Axogen expects the acquisition to add to revenue growth, adjusted EBITDA margin and adjusted earnings per share in the first year after closing while keeping the company free-cash-flow positive. Management also expects BioCircuit to add to 2027 revenue and improve gross margin and adjusted EBITDA margin, assuming the purchase closes in 2026. Those statements are forward-looking company expectations, not guaranteed outcomes. Axogen plans to update its full-year 2026 guidance after the acquisition closes and provide full-year 2027 guidance in the first quarter of next year.

The acquisition is structured as a merger and targets a fourth-quarter close

Although Axogen is buying BioCircuit for cash, the legal structure uses a merger agreement. An Axogen subsidiary, Omega Merger Sub, will merge into BioCircuit, with BioCircuit surviving as a wholly owned Axogen subsidiary. Describing the overall corporate action as an acquisition is therefore consistent with the economic result, while the merger language explains how ownership will be transferred under the signed agreement.

The companies expect the acquisition to close in the fourth quarter of 2026. Conditions include consent under an inbound intellectual-property license, conversion of BioCircuit’s outstanding convertible notes into common shares before closing, and the spin-out of an unrelated electronics research and development business to BioCircuit shareholders. Axogen said the acquisition is not expected to require regulatory approvals.

The agreement also gives either side a termination right if the acquisition has not been completed by December 31, subject to the contract’s limitations, and the SEC filing says there is no termination fee. Those conditions make the September 11 stock-offering close the nearer-term milestone, followed by BioCircuit’s required corporate steps and the planned fourth-quarter acquisition close.

For Axogen, the financing represents a large capital raise relative to its recent operating scale. Second-quarter revenue was $69.7 million, up 23.1% from a year earlier, while the company reported $4.1 million of free cash flow for the first six months of 2026. Management’s standing full-year outlook before the BioCircuit purchase called for at least $279 million of revenue, gross margin of at least 73% and positive free cash flow. The company has said it will revisit that outlook after BioCircuit is brought under Axogen ownership.